

Filed: February 7, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

YEDA RESEARCH & DEVELOPMENT CO. LTD.

Patent Owner.

Patent No. 8,399,413

PETITION FOR *INTER PARTES* REVIEW

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	MANDATORY NOTICES	2
	A. Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1)).....	2
	B. Related Matters (37 C.F.R. § 42.8(b)(2)).....	2
	C. Identification of Counsel (37 C.F.R. § 42.8(b)(3)) and Service Information (37 C.F.R. § 42.8(b)(4))	3
	D. Service Information (37 C.F.R. § 42.8(b)(4)).....	3
III.	GROUND FOR STANDING AND PROCEDURAL STATEMENT	3
IV.	IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED	3
V.	THRESHOLD REQUIREMENT FOR <i>INTER PARTES</i> REVIEW	4
VI.	STATEMENT OF REASONS FOR THE RELIEF REQUESTED	5
	A. Summary of the Argument.....	5
	B. Background of the '413 Patent.....	7
	1. The '413 Patent.....	7
	2. The Prosecution of the '413 Patent.....	9
	C. Level of Ordinary Skill in the Art	12
	D. Claim Construction.....	12
	E. Patents and Printed Publications Relied On In This Petition.....	15
	1. Pinchasi (Ex. 1005).....	15
	2. 1996 FDA SBOA (Ex. 1007A).....	16
	3. Flechter 2002A (Ex. 1008)	18
	4. Prior Art Informing the General Knowledge of the Ordinarily-Skilled Artisan	20
	F. Ground 1: Claims 1-6 and 8-20 Are Anticipated by Pinchasi.	20
	1. Independent Claim 1 Is Anticipated by Pinchasi.....	20
	2. Independent Claim 19 Is Anticipated by Pinchasi.....	24
	3. Independent Claim 20 Is Anticipated by Pinchasi.....	25
	4. Dependent Claims 2-6 and 8-15 Are Anticipated by Pinchasi.	26

a.	Pinchasi expressly disclosed the further limitations of claims 2-3 and 8.	26
b.	Pinchasi expressly discloses the further limitations of claims 5 and 12-13.	28
c.	Pinchasi expressly disclosed the further limitations of claim 6.	29
d.	Pinchasi expressly discloses the further limitations of claim 14-15.	30
e.	Pinchasi discloses every limitation of dependent claims 16-18.	31
f.	Pinchasi discloses every limitation of dependent claims 4 and 9-11.	32
G.	Summary of Petitioner’s Obviousness Positions.	34
1.	The Law of Obviousness.	34
2.	The Prior Art Renders the Claims Obvious.	38
a.	Investigation into Different Dosing Protocols for GA Therapy.	38
b.	The Prior Art Motivated a Person of Ordinary Skill to Investigate Different Dosing Protocols and Provided A Reasonable Expectation of Success.	41
H.	Ground 2: Claims 1-20 Are Unpatentable As Obvious over Pinchasi.	45
1.	Independent Claims 1, 19 and 20 Are Obvious over Pinchasi.	45
a.	Dependent claim 7 is Obvious in View of Pinchasi.	50
2.	Dependent Claims 2-6 and 8-18 Are Obvious in View of Pinchasi.	51
I.	Ground 3: Claims 1-20 Are Unpatentable As Obvious over Pinchasi and the 1996 SBOA.	51
1.	Independent Claims 1, 19 and 20 Are Obvious over Pinchasi in view of the 1996 FDA SBOA.	51
2.	Dependent Claims 2-18 Are Obvious over Pinchasi and the 1996 SBOA.	55

J.	Ground 4: Claims 1-20 Are Unpatentable As Obvious over Pinchasi and Flechter 2002A.....	55
1.	Independent Claims 1, 15, and 19 Are Obvious in View of Pinchasi and Flechter 2002A.....	55
2.	Dependent Claims 2-18 Are Obvious over Pinchasi and Flechter 2002A.....	56
K.	Any Secondary Considerations Fail to Overcome the Showing of Obviousness.	56
1.	The Methods Recited in the '413 Patent Produced No Relevant Unexpected Results.	57
2.	The '413 Patent Satisfied No Long-Felt But Unmet Need.....	58
3.	Copying By Generic Drug Makers Is Irrelevant.....	59

TABLE OF AUTHORITIES

Page(s)

CASES

<i>Baldwin Graphic Sys., Inc. v. Siebert, Inc.</i> , 512 F.3d 1338 (Fed. Cir. 2008)	15
<i>Bayer Healthcare Pharms., Inc. v. Watson Pharms., Inc.</i> , 713 F.3d 1369 (Fed. Cir. 2013)	59
<i>Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.</i> , 752 F.3d 967 (Fed. Cir. 2014)	57
<i>Galderma Labs. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013)	58
<i>Gillette Co. v. Energizer Holdings Inc.</i> , 405 F.3d 1367 (Fed. Cir. 2005)	13, 14, 15, 23
<i>Graham v. John Deere Co. of Kan. City</i> , 383 U.S. 1 (1966).....	35
<i>Hoffmann-La Roche Inc. v. Apotex Inc.</i> , 748 F.3d 1326 (Fed. Cir. 2014)	37, 57, 58
<i>In re Baxter Travenol Labs.</i> , 952 F.2d 388 (Fed. Cir. 1991)	29, 33
<i>In re Cronyn</i> , 890 F.2d 1158 (Fed. Cir. 1989)	17
<i>In re Cuozzo Speed Techs., LLC</i> , No. 2014-31, Slip opinion (Fed. Cir. Feb. 4, 2015).....	13
<i>In re Kubin</i> , 561 F.3d 1351 (Fed. Cir. 2009)	34, 37, 38
<i>In re Lister</i> , 583 F.3d 1307 (Fed. Cir. 2009)	18
<i>In re PepperBall Techs., Inc.</i> , 469 F. App'x 878 (Fed. Cir. 2012).....	58

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.